did the fda ban tirzepatide on Compounded GLP-1 Drugs: What to Know FDA's tirzepatide decision creates uncertainty

The tumor uptake values of our PEGylated probe at 60-min post-injection in the resected organs of mice bearing INS-1 xenografts (Right thigh: 37.3 4.5%ID/g, Inside pancreas: 37.7 4.4%ID/g) showed comparable or higher values than those of other 18 F-labeled non-PEGylated modified exendin-4 probes

GLP-1 treatment may not be appropriate for patients who are pregnant, breastfeeding, planning pregnancy, or who have certain personal or family medical histories, including medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2

Indianapolis, IN, USA: Eli Lilly and Company (2023)

Absence of documentation should be considered a red flag